Exposure to azithromycin and the effect of co-administration of rifampicin in patients with non-tuberculous mycobacterial disease
Journal of Antimicrobial Chemotherapy · 03.06.2026 · 81 (7)
DOI: 10.1093/jac/dkag206 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 13.06.2026. Verfasst von M P Rodgers und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Pharmacology & Toxicology, Radboudumc Community for Infectious Diseases, Radboud University Medical Center, Nijmegen, The Net…. Hauptthemen laut MEDLINE: Azithromycin, Rifampin, Anti-Bacterial Agents, Mycobacterium Infections, Nontuberculous. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objectives
Azithromycin is a key drug in the treatment of most non-tuberculous mycobacterial (NTM) diseases. Its exposure may be decreased by rifampicin co-administration, but to what extent is largely unknown. We measured azithromycin exposure in an NTM disease patient population and quantified the effect of rifampicin co-administration.
Methods
We retrospectively collected plasma azithromycin area-under-the-curve from 0 to 6 hours after administration in mg/L*hours (AUC0-6h), peak (Cmax), and trough (Cmin) concentrations from the TDM service at Radboudumc, The Netherlands. Azithromycin exposure measures were compared between patients with and without concurrent rifampicin use, and within patients who had rifampicin stopped during treatment.
Results
We analysed data of 130 patients, of whom 59% had NTM pulmonary disease. The azithromycin geometric mean of AUC0-6h in patients with (n = 48) and without (n = 82) rifampicin were 0.90 versus 1.83 mg/L*h, Cmax 0.22 versus 0.46 mg/L, and Cmin 0.043 versus 0.13 mg/L, respectively. A within-patient comparison in 14 subjects showed geometric means of AUC0-6h, Cmax, and Cmin (90%-CI) with rifampicin were 62% (45%–74%), 58% (38%–72%) and 66% (48%–77%) lower than without rifampicin. Interventions based on TDM enabled a strong increase in exposure to azithromycin. No association between azithromycin exposure and disease outcomes was shown, but the number of patients in these analyses was small.
Conclusions
This study provides new population exposure data for TDM of azithromycin in NTM disease. Rifampicin co-administration reduces azithromycin exposure by at least half, underscoring the need for upfront azithromycin dose adjustment, application of TDM, or considering alternative drugs for rifampicin, also considering controversy around its effectiveness and adverse effects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Pharmacology & Toxicology, Radboudumc Community for Infectious Diseases, Radboud University Medical Center, Nijmegen, The Netherlands.
- Radboudumc, Department of Medical Microbiology, Radboudumc Community for Infectious Diseases, Radboud University Medical Center, Nijmegen, The Netherlands.
- Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark.
- Radboudumc, Department of Internal Medicine, Radboudumc Community for Infectious Diseases, Radboud University Medical Center, Nijmegen, The Netherlands.
- Department of Pulmonary Diseases, Radboudumc Community for Infectious Diseases, Radboud University Medical Center, Nijmegen, The Netherlands.
ORCID-Profile: M P Rodgers, R Stemkens, A van Laarhoven, A Lemson, J van Ingen
Zitieren
APA
Rodgers, M. P., Stemkens, R., Dahl, V. N., van Laarhoven, A., Hoefsloot, W., Lemson, A., van Ingen, J., & Aarnoutse, R. E. (2026). Exposure to azithromycin and the effect of co-administration of rifampicin in patients with non-tuberculous mycobacterial disease. Journal of Antimicrobial Chemotherapy, 81(7). https://doi.org/10.1093/jac/dkag206
Vancouver
Rodgers MP, Stemkens R, Dahl VN, van Laarhoven A, Hoefsloot W, Lemson A, et al. Exposure to azithromycin and the effect of co-administration of rifampicin in patients with non-tuberculous mycobacterial disease. Journal of Antimicrobial Chemotherapy. 2026;81(7). doi:10.1093/jac/dkag206
BibTeX
@article{Rodgers2026,
author = {Rodgers, M P and Stemkens, R and Dahl, V N and van Laarhoven, A and Hoefsloot, W and Lemson, A and van Ingen, J and Aarnoutse, R E},
title = {Exposure to azithromycin and the effect of co-administration of rifampicin in patients with non-tuberculous mycobacterial disease},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2026},
volume = {81},
number = {7},
doi = {10.1093/jac/dkag206}
}
EUVIMED